Alfons Macaya Selected Research

Lymphangioleiomyomatosis (Lymphangiomyomatosis)

1/2019	Treatment Patterns and Use of Resources in Patients With Tuberous Sclerosis Complex: Insights From the TOSCA Registry.
1/2017	TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alfons Macaya Research Topics

Disease

17	Tuberous Sclerosis (Bourneville's Disease) 01/2022 - 06/2014
9	Migraine Disorders (Migraine) 01/2023 - 05/2009
7	Ataxia (Dyssynergia) 12/2022 - 01/2015
7	Epilepsy (Aura) 10/2021 - 04/2016
6	Neurodevelopmental Disorders 01/2023 - 01/2015
5	Seizures (Absence Seizure) 01/2021 - 08/2013
5	Rare Diseases (Rare Disease) 01/2021 - 11/2014
5	Angiomyolipoma 01/2020 - 04/2016
5	Astrocytoma (Pilocytic Astrocytoma) 01/2019 - 04/2016
4	Parkinsonian Disorders (Parkinsonism) 01/2023 - 01/2020
4	Chorea (Rheumatic Chorea) 11/2022 - 01/2018
4	Cerebellar Diseases (Cerebellar Syndrome) 12/2018 - 10/2015
3	Atrophy 04/2024 - 01/2015
3	Dystonia (Limb Dystonia) 11/2022 - 02/2006
3	Migraine with Aura (Familial Hemiplegic Migraine) 02/2018 - 05/2009
3	Inborn Genetic Diseases (Disease, Hereditary) 01/2017 - 11/2014
2	Movement Disorders (Movement Disorder) 01/2023 - 04/2016
2	Paraplegia (Spastic Paraplegia) 12/2022 - 01/2020
2	Intellectual Disability (Idiocy) 12/2022 - 01/2019
2	Hyperkinesis 11/2022 - 01/2018
2	Episodic Ataxia 10/2022 - 01/2017
2	Infantile Spasms (West Syndrome) 01/2021 - 03/2019
2	Neurologic Manifestations (Neurological Manifestations) 01/2021 - 06/2014
2	Neoplasms (Cancer) 01/2021 - 06/2014
2	Leukoencephalopathies 01/2020 - 07/2006
2	Lymphangioleiomyomatosis (Lymphangiomyomatosis) 01/2019 - 01/2017
2	Muscle Hypotonia (Hypotonia) 01/2019 - 01/2019
2	Nervous System Diseases (Neurological Disorders) 11/2016 - 01/2015
2	Dyskinesias (Dyskinesia) 04/2016 - 01/2012
2	Migraine without Aura (Common Migraine) 09/2009 - 05/2009
1	Tremor (Tremors) 01/2023
1	Microcephaly 12/2022
1	Autistic Disorder (Autism) 10/2022
1	Male Infertility (Male Sterility) 01/2022
1	Myoclonic dystonia 08/2021
1	Megalencephaly 01/2021
1	Ehlers-Danlos Syndrome (Syndrome, Ehlers-Danlos) 01/2021
1	Leigh Disease (Leigh's Disease) 01/2021
1	Ischemic Stroke 07/2020
1	Pallidopyramidal syndrome 01/2020
1	Hereditary Spastic Paraplegia 01/2020
1	Frontotemporal Dementia (Semantic Dementia) 01/2020
1	Cerebellar Ataxia (Dysmetria) 01/2020
1	Hypertension (High Blood Pressure) 01/2020
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2020
1	Huntington Disease (Huntington's Disease) 01/2020
1	Congenital Myasthenic Syndromes (Myasthenia Gravis, Congenital) 05/2019
1	Muscle Weakness 05/2019
1	Headache (Headaches) 01/2019
1	Dysarthria (Spastic Dysarthria) 12/2018
1	Stroke (Strokes) 02/2018
1	Channelopathies 02/2018

Drug/Important Bio-Agent (IBA)

18	trans-sodium crocetinate (crocetin)IBA 01/2022 - 06/2014
4	Congenital disorder of glycosylation type 1AIBA 12/2018 - 10/2015
4	phosphomannomutaseIBA 12/2018 - 10/2015
3	Everolimus FDA Link 01/2022 - 04/2016
3	voltage-dependent calcium channel (P-Q type)IBA 02/2018 - 01/2015
2	Topiramate (Topamax)FDA LinkGeneric 01/2023 - 01/2017
2	Levodopa (L Dopa)FDA LinkGeneric 01/2023 - 01/2020
2	Valproic Acid (Depakote)FDA LinkGeneric 01/2023 - 01/2017
2	SteroidsIBA 01/2021 - 08/2013
2	IronIBA 01/2020 - 01/2020
2	MTOR InhibitorsIBA 01/2019 - 04/2016
2	Calcium Channels (Calcium Channel)IBA 01/2017 - 05/2014
2	GTP-Binding Proteins (G-Protein)IBA 04/2016 - 07/2009
2	Amino Acids FDA Link 01/2015 - 07/2009
2	Proteins (Proteins, Gene)FDA Link 01/2010 - 05/2009
1	Indicators and Reagents (Reagents)IBA 04/2024
1	Transfer RNA (tRNA)IBA 01/2023
1	Ligases (Synthetase)IBA 01/2023
1	Serine-tRNA LigaseIBA 12/2022
1	Neurotransmitter Agents (Neurotransmitter)IBA 11/2022
1	Dopamine Agents (Dopaminergic Agents)IBA 11/2022
1	Facilitative Glucose Transport Proteins (Glucose Transporter)IBA 11/2022
1	6-pyruvoyltetrahydropterin synthase (PTPS)IBA 11/2022
1	Acetazolamide (Diamox)FDA LinkGeneric 10/2022
1	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 10/2021
1	Sarcoglycans (beta Sarcoglycan)IBA 08/2021
1	Valine (L-Valine)FDA Link 01/2021
1	beta-cyclodextrin tetradecasulfate (CTDS)IBA 01/2021
1	Vigabatrin FDA Link 01/2021
1	P-2 (P 2)IBA 01/2021
1	Complement System Proteins (Complement)IBA 12/2020
1	TOR Serine-Threonine KinasesIBA 01/2020
1	Quinidine (Chinidin)FDA LinkGeneric 12/2019
1	AMPA Receptors (AMPA Receptor)IBA 12/2019
1	Cholinesterase Inhibitors (Anticholinesterases)IBA 05/2019
1	gamma-Aminobutyric Acid (GABA)IBA 03/2019
1	Aminobutyrates (Aminobutyric Acid)IBA 03/2019
1	lipoarabinomannan (LAM)IBA 01/2019
1	NucleotidesIBA 01/2019
1	Caffeine (No Doz)FDA LinkGeneric 01/2019
1	Vesicle-Associated Membrane Protein 2 (VAMP2)IBA 01/2019
1	Guanosine Monophosphate (5' Guanylic Acid)IBA 01/2018

Therapy/Procedure

5	Therapeutics 11/2022 - 04/2016
2	Ketogenic Diet 11/2022 - 04/2016
1	Deep Brain Stimulation 11/2022
1	Treatment Delay 12/2020
1	Thrombectomy 07/2020
1	Nutritional Support (Artificial Feeding) 01/2019